Xencor Inc

Several biotech stocks reached 52-week highs on July 20, 2026, driven by upcoming clinical trial launches and data readouts. Xencor Inc. hit $20.26, closing up 7%, as it advances XmAb942 in a Phase 2b ulcerative colitis trial with interim results expected by year-end 2026, and two bispecific antibodies in Phase 1 with data due in the second half of 2026. Hemab Therapeutics Holdings Inc. reached $52.15 after reporting positive Phase 2 data for Sutacimig in Glanzmann thrombasthenia and Factor VIII deficiency, showing an 84% reduction in mean annualized treated bleeding rate, along with positive interim Phase 2 results for HMB-002 in Von Willebrand's disease and the launch of HMB-003 for heavy menstrual bleeding. Monopar Therapeutics Inc. hit $115 following positive Phase 3 results for ALXN1840 in Wilson disease, for which it received a Rare Pediatric Disease voucher and plans an NDA submission by mid-2026, while also advancing MNPR-101 in Phase 1 for solid tumors. SOPHiA GENETICS SA rose over 7% to a 52-week high of $6.50, reporting first-quarter revenue of $21.7 million, up 22% year-over-year, and guiding for full-year 2026 revenue of $92 million to $94 million, representing 20% to 22% growth. Aclaris Therapeutics Inc. is advancing Bosakitug in a Phase 2 atopic dermatitis trial with topline results expected in the fourth quarter of 2026, ATI-052 in a Phase 1b for atopic dermatitis and a Phase 2b asthma program starting in the fourth quarter, and ATI-2138 in a planned Phase 2 basket study for lichen planus in the second half of 2026.

Shares of Xencor surged 17% on Friday after the company announced that its Phase 1 candidate XmAb819 earned a proffered paper oral presentation slot at ESMO 2026. The stock rose $2.52 to close at $17.47 on volume of about 1.68 million shares, which was 1.7 times the one-month average. XmAb819 is being studied in advanced clear cell renal cell carcinoma, and the high-visibility oral format is expected to draw meaningful attention to the program. Prior to the rally, Xencor shares had drifted lower over the past week.